From WikiPathways

Revision as of 14:47, 18 October 2017 by Marvin M2 (Talk | contribs)
Jump to: navigation, search

The purpose of this portal is to create a collection of AOPs on the molecular level for the AOPs that are, or will be created for the EU-ToxRisk program, in which Open PHACTS Foundation (OPF) is responsible for AOP creation. The subjects of the first AOPs are linked to the use cases of the EU-ToxRisk program, and there will be a team of experts involved in the creation of each AOP.

The proposed list of the first set of AOPs to be created, some are more defined than others:

  • Reduced mitochondrial activity leads to cholestasis
  • Liver fibrosis
  • Unfolded protein response-mediated liver toxicity
  • Mitotoxicity-mediated hepatotoxicity
  • Inhibition of mitochondrial complex I of nigra-striatal neurons leads to parkinsonian motor deficits
  • Peripheral neuropathy caused by microtubule interacting drugs
  • Oxidative reactivity leads to chemical-induced fanconi syndrome
  • Oxidative reactivity leads to acceleration of chronic kidney disease
  • Compound accumulation via Megalin/Cubilin uptake leads to acute and chronic kidney disease
  • Renal proximal tubular uptake via organic cation transporters leads to...
  • Oxidant-induced pulmonary emphysema
  • α-diketone-induced bronchiolitis obliterans
  • HDAC inhibition leads to neural tube defects
  • Cyt p450 inhibition leads to Feminization and Masculinization
  • Estrogen/androgen ...
  • Oxidative stress-induced hepatoxicity
  • Inflammatory cytokine-induced cell death
  • HDAC inhibition leads to impaired craniofacial development

Basic strategies and principles for general AOPs are described in this paper:

Villeneuve et al. (2014). Adverse Outcome Pathway (AOP) Development I: Strategies and Principles. Toxicological Sciences PubMed

Personal tools